{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:07:39Z","timestamp":1770354459760,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer (PCa) is the most prevalent malignancy among men worldwide. Advanced prostate cancer is characterized by aggressive progression, limited therapeutic response, and poor prognosis. Elucidating its oncogenic mechanisms may provide new opportunities for targeted intervention. Increasing evidence suggests that modulating cytoprotective autophagy represents a promising strategy for improving cancer treatment efficacy and overcoming drug resistance. Here, we identified the G protein subunit GNG4 as a crucial regulator of prostate cancer development. GNG4 expression was markedly elevated in advanced prostate cancer phenotypes and positively correlated with tumor survival, apoptosis, and migration. Further analysis demonstrated that GNG4 depletion suppressed autophagy and enhanced cellular sensitivity to enzalutamide. Mechanistically, GNG4 interacts with GNB1 to stabilize the downstream effector protein GNAI3 through the ubiquitination-proteasome pathway. These three distinct G protein subunits form a functional complex that regulates intracellular autophagy and subsequently influences the malignant behavior of prostate cancer. Furthermore, inhibition of autophagy or GNG4 knockdown significantly increased the antitumor efficacy of enzalutamide both in vitro and in vivo. Our findings identified GNG4 as a pivotal modulator of prostate cancer progression and proposed it as a promising therapeutic target to enhance the clinical response to enzalutamide.<\/jats:p>","DOI":"10.1038\/s41419-026-08421-w","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:45:54Z","timestamp":1769640354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting GNG4 inhibits tumor progression and restores enzalutamide sensitivity in prostate cancer by suppressing autophagy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-435X","authenticated-orcid":false,"given":"Lei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanshuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-9433","authenticated-orcid":false,"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-8543","authenticated-orcid":false,"given":"Chun-Wu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"8421_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8421_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8421_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79:263\u201382.","journal-title":"Eur Urol"},{"key":"8421_CR4","doi-asserted-by":"publisher","first-page":"e2337272","DOI":"10.1001\/jamanetworkopen.2023.37272","volume":"6","author":"KM Rasmussen","year":"2023","unstructured":"Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, et al. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2023;6:e2337272.","journal-title":"JAMA Netw Open"},{"key":"8421_CR5","doi-asserted-by":"crossref","unstructured":"Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019;38:e99599.","DOI":"10.15252\/embj.201899599"},{"key":"8421_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2165\/00003495-200666060-00007","volume":"66","author":"K Wellington","year":"2006","unstructured":"Wellington K, Keam SJ. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer. Drugs. 2006;66:837\u201350.","journal-title":"Drugs"},{"key":"8421_CR7","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med"},{"key":"8421_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"8421_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"8421_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017;71:151\u20134.","journal-title":"Eur Urol"},{"key":"8421_CR11","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"8421_CR12","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"8421_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrc3521","volume":"13","author":"M O\u2019Hayre","year":"2013","unstructured":"O\u2019Hayre M, V\u00e1zquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer. 2013;13:412\u201324.","journal-title":"Nat Rev Cancer"},{"key":"8421_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1124\/pr.111.005603","volume":"65","author":"SM Khan","year":"2013","unstructured":"Khan SM, Sleno R, Gora S, Zylbergold P, Laverdure J-P, Labb\u00e9 J-C, et al. The expanding roles of G\u03b2\u03b3 subunits in G protein-coupled receptor signaling and drug action. Pharm Rev. 2013;65:545\u201377.","journal-title":"Pharm Rev"},{"key":"8421_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/369418a0","volume":"369","author":"P Crespo","year":"1994","unstructured":"Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature. 1994;369:418\u201320.","journal-title":"Nature"},{"key":"8421_CR16","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jcmm.17847","volume":"27","author":"J Wang","year":"2023","unstructured":"Wang J, Wang Y, Zhou J, Cai M, Guo P, Du T, et al. GNG4, as a potential predictor of prognosis, is correlated with immune infiltrates in colon adenocarcinoma. J Cell Mol Med. 2023;27:2517\u201332.","journal-title":"J Cell Mol Med"},{"key":"8421_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41416-021-01366-1","volume":"125","author":"H Tanaka","year":"2021","unstructured":"Tanaka H, Kanda M, Miwa T, Umeda S, Sawaki K, Tanaka C, et al. G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer. Br J Cancer. 2021;125:220\u20138.","journal-title":"Br J Cancer"},{"key":"8421_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00330-1","volume":"10","author":"D Zhu","year":"2021","unstructured":"Zhu D, Gu X, Lin Z, Yu D, Wang J. High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis. Oncogenesis. 2021;10:43.","journal-title":"Oncogenesis"},{"key":"8421_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/1759-7714.14265","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Zhu W, Yuan S, Wang Y, Zhang Q, Zheng H, et al. High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma. Thorac Cancer. 2022;13:369\u201379.","journal-title":"Thorac Cancer"},{"key":"8421_CR20","doi-asserted-by":"crossref","unstructured":"Duan L, Liu X, Luo Z, Zhang C, Wu C, Mu W, et al. G-Protein Subunit Gamma 4 as a Potential biomarker for predicting the response of chemotherapy and immunotherapy in bladder cancer. Genes. 2022;13:693.","DOI":"10.3390\/genes13040693"},{"key":"8421_CR21","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1038\/sj.onc.1208649","volume":"24","author":"EN Maina","year":"2005","unstructured":"Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, et al. Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene. 2005;24:4549\u201358.","journal-title":"Oncogene"},{"key":"8421_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1126\/science.290.5497.1717","volume":"290","author":"DJ Klionsky","year":"2000","unstructured":"Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717\u201321.","journal-title":"Science"},{"key":"8421_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06154-8","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Yao S, Yang H, Liu S, Wang Y. Autophagy: Regulator of cell death. Cell Death Dis. 2023;14:648.","journal-title":"Cell Death Dis"},{"key":"8421_CR24","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108863","volume":"40","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, et al. Autophagy in major human diseases. EMBO J. 2021;40:e108863.","journal-title":"EMBO J"},{"key":"8421_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrurol.2014.196","volume":"11","author":"JM Farrow","year":"2014","unstructured":"Farrow JM, Yang JC, Evans CP. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014;11:508\u201316.","journal-title":"Nat Rev Urol"},{"key":"8421_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207257","volume":"10","author":"T Jiang","year":"2023","unstructured":"Jiang T, Zhu J, Jiang S, Chen Z, Xu P, Gong R, et al. Targeting lncRNA DDIT4-AS1 Sensitizes triple negative breast cancer to chemotherapy via suppressing of autophagy. Adv Sci. 2023;10:e2207257.","journal-title":"Adv Sci"},{"key":"8421_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41388-022-02573-7","volume":"42","author":"N Nikesitch","year":"2023","unstructured":"Nikesitch N, Beraldi E, Zhang F, Adomat H, Bell R, Suzuki K, et al. Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling. Oncogene. 2023;42:748\u201358.","journal-title":"Oncogene"},{"key":"8421_CR28","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/onc.2014.25","volume":"33","author":"HG Nguyen","year":"2014","unstructured":"Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, et al. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014;33:4521\u201330.","journal-title":"Oncogene"},{"key":"8421_CR29","doi-asserted-by":"crossref","unstructured":"Elshazly AM, Gewirtz DA. Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer. Cancers. 2023;15:5029.","DOI":"10.3390\/cancers15205029"},{"key":"8421_CR30","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.7150\/thno.58655","volume":"11","author":"A Mukha","year":"2021","unstructured":"Mukha A, Kahya U, Linge A, Chen O, Lock S, Lukiyanchuk V, et al. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics. 2021;11:7844\u201368.","journal-title":"Theranostics"},{"key":"8421_CR31","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u2013D46.","journal-title":"Nucleic Acids Res"},{"key":"8421_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00299-9","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, et al. An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun. 2017;8:347.","journal-title":"Nat Commun"},{"key":"8421_CR33","doi-asserted-by":"publisher","first-page":"W310","DOI":"10.1093\/nar\/gkl206","volume":"34","author":"A Tovchigrechko","year":"2006","unstructured":"Tovchigrechko A, Vakser IA. GRAMM-X public web server for protein-protein docking. Nucleic Acids Res. 2006;34:W310\u2013W4.","journal-title":"Nucleic Acids Res"},{"key":"8421_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13046-022-02293-6","volume":"41","author":"M Ashrafizadeh","year":"2022","unstructured":"Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, et al. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. J Exp Clin Cancer Res. 2022;41:105.","journal-title":"J Exp Clin Cancer Res"},{"key":"8421_CR35","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1073\/pnas.0611434104","volume":"104","author":"A Gohla","year":"2007","unstructured":"Gohla A, Klement K, Piekorz RP, Pexa K, vom Dahl S, Spicher K, et al. An obligatory requirement for the heterotrimeric G protein Gi3 in the antiautophagic action of insulin in the liver. Proc Natl Acad Sci USA. 2007;104:3003\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8421_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/15548627.2021.1934271","volume":"18","author":"X Wang","year":"2022","unstructured":"Wang X, Wei Z, Lan T, He Y, Cheng B, Li R, et al. CCDC88A\/GIV promotes HBV replication and progeny secretion via enhancing endosomal trafficking and blocking autophagic degradation. Autophagy. 2022;18:357\u201374.","journal-title":"Autophagy"},{"key":"8421_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1124\/mol.117.111062","volume":"93","author":"K Sriram","year":"2018","unstructured":"Sriram K, Insel PA. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?. Mol Pharm. 2018;93:251\u20138.","journal-title":"Mol Pharm"},{"key":"8421_CR38","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1002\/anie.201301924","volume":"52","author":"RJ Lefkowitz","year":"2013","unstructured":"Lefkowitz RJ. A brief history of G-protein coupled receptors (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52:6366\u201378.","journal-title":"Angew Chem Int Ed Engl"},{"key":"8421_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature22070","volume":"545","author":"T Flock","year":"2017","unstructured":"Flock T, Hauser AS, Lund N, Gloriam DE, Balaji S, Babu MM. Selectivity determinants of GPCR-G-protein binding. Nature. 2017;545:317\u201322.","journal-title":"Nature"},{"key":"8421_CR40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1210\/edrv-10-3-317","volume":"10","author":"GL Johnson","year":"1989","unstructured":"Johnson GL, Dhanasekaran N. The G-protein family and their interaction with receptors. Endocr Rev. 1989;10:317\u201331.","journal-title":"Endocr Rev"},{"key":"8421_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.tips.2018.01.001","volume":"39","author":"W Wang","year":"2018","unstructured":"Wang W, Qiao Y, Li Z. New Insights into Modes of GPCR Activation. Trends Pharm Sci. 2018;39:367\u201386.","journal-title":"Trends Pharm Sci"},{"key":"8421_CR42","doi-asserted-by":"crossref","unstructured":"Wang C, Zhang Y, Gao W-Q. The evolving role of immune cells in prostate cancer. Cancer Lett. 2022;525:9\u201321.","DOI":"10.1016\/j.canlet.2021.10.027"},{"key":"8421_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd3802","volume":"11","author":"DC Rubinsztein","year":"2012","unstructured":"Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"8421_CR44","doi-asserted-by":"crossref","unstructured":"Sethi G, Shanmugam MK, Warrier S, Merarchi M, Arfuso F, Kumar AP, et al. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients. 2018;10:645.","DOI":"10.3390\/nu10050645"},{"key":"8421_CR45","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.3892\/mmr.2016.5750","volume":"14","author":"C Nie","year":"2016","unstructured":"Nie C, Zhou J, Qin X, Shi X, Zeng Q, Liu J, et al. Diosgenin\u2011induced autophagy and apoptosis in a human prostate cancer cell line. Mol Med Rep. 2016;14:4349\u201359.","journal-title":"Mol Med Rep"},{"key":"8421_CR46","first-page":"3461","volume":"11","author":"J Zhang","year":"2019","unstructured":"Zhang J, Xie J-J, Zhou S-J, Chen J, Hu Q, Pu J-X, et al. Diosgenin inhibits the expression of NEDD4 in prostate cancer cells. Am J Transl Res. 2019;11:3461\u201371.","journal-title":"Am J Transl Res"},{"key":"8421_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00345-018-2385-5","volume":"37","author":"A Mortezavi","year":"2019","unstructured":"Mortezavi A, Salemi S, Kranzb\u00fchler B, Gross O, Sulser T, Simon H-U, et al. Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. World J Urol. 2019;37:351\u20138.","journal-title":"World J Urol"},{"key":"8421_CR48","doi-asserted-by":"publisher","first-page":"9942","DOI":"10.18632\/aging.204427","volume":"14","author":"Y Feng","year":"2022","unstructured":"Feng Y, Cao H, Song Z, Chen L, Wang D, Gao R. Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer. Aging. 2022;14:9942\u201350.","journal-title":"Aging"},{"key":"8421_CR49","first-page":"181","volume":"34","author":"X Ma","year":"2019","unstructured":"Ma X, Zou L, Li X, Chen Z, Lin Z, Wu X. Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer. Cancer Biother Radiopharm. 2019;34:181\u20138.","journal-title":"Cancer Biother Radiopharm"},{"key":"8421_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22474","volume":"34","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yang T, Chen S, Qi S, Zhang Z, Xu Y. Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells. J Biochem Mol Toxicol. 2020;34:e22474.","journal-title":"J Biochem Mol Toxicol"},{"key":"8421_CR51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1021\/nn103044z","volume":"5","author":"AL Becker","year":"2011","unstructured":"Becker AL, Orlotti NI, Folini M, Cavalieri F, Zelikin AN, Johnston APR, et al. Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano. 2011;5:1335\u201344.","journal-title":"ACS Nano"},{"key":"8421_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110181","volume":"127","author":"Y Chen","year":"2020","unstructured":"Chen Y, Deng Y, Zhu C, Xiang C. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2020;127:110181.","journal-title":"Biomed Pharmacother"},{"key":"8421_CR53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/15548627.2017.1378838","volume":"14","author":"L Yu","year":"2018","unstructured":"Yu L, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. Autophagy. 2018;14:207\u201315.","journal-title":"Autophagy"},{"key":"8421_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24844-9","volume":"12","author":"H N\u016fskov\u00e1","year":"2021","unstructured":"N\u016fskov\u00e1 H, Serebryakova MV, Ferrer-Caelles A, Sachsenheimer T, L\u00fcchtenborg C, Miller AK, et al. Stearic acid blunts growth-factor signaling via oleoylation of GNAI proteins. Nat Commun. 2021;12:4590.","journal-title":"Nat Commun"},{"key":"8421_CR55","doi-asserted-by":"crossref","unstructured":"Guda RS, Odegaard KE, Tan C, Schaal VL, Yelamanchili SV, Pendyala G. Integrated systems analysis of mixed neuroglial cultures proteome post oxycodone exposure. Int J Mol Sci. 2021;22:6421.","DOI":"10.3390\/ijms22126421"},{"key":"8421_CR56","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ncb3001","volume":"16","author":"SE Williams","year":"2014","unstructured":"Williams SE, Ratliff LA, Postiglione MP, Knoblich JA, Fuchs E. Par3-mInsc and G\u03b1i3 cooperate to promote oriented epidermal cell divisions through LGN. Nat Cell Biol. 2014;16:758\u201369.","journal-title":"Nat Cell Biol"},{"key":"8421_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01340-7","volume":"15","author":"C Song","year":"2022","unstructured":"Song C, Pan S, Li D, Hao B, Lu Z, Lai K, et al. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma. BMC Med Genomics. 2022;15:198.","journal-title":"BMC Med Genomics"},{"key":"8421_CR58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1083\/jcb.200712066","volume":"182","author":"P Ghosh","year":"2008","unstructured":"Ghosh P, Garcia-Marcos M, Bornheimer SJ, Farquhar MG. Activation of Galphai3 triggers cell migration via regulation of GIV. J Cell Biol. 2008;182:381\u201393.","journal-title":"J Cell Biol"},{"key":"8421_CR59","doi-asserted-by":"crossref","unstructured":"Raza A, Yen M-C, Anuraga G, Shahzadi I, Mazhar MW, Ta HDK, et al. Comparative Analysis of the GNAI Family Genes in Glioblastoma through Transcriptomics and Single-Cell Technologies. Cancers. 2023;15:5112.","DOI":"10.3390\/cancers15205112"},{"key":"8421_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.canlet.2014.11.013","volume":"356","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Yao J, Huan L, Lian J, Bao C, Li Y, et al. GNAI3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR-222 in hepatocellular carcinoma. Cancer Lett. 2015;356:978\u201384.","journal-title":"Cancer Lett"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08421-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:03:50Z","timestamp":1770303830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08421-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8421"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08421-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Experiments involving animals were performed in compliance with the ethical standards established by the animal ethics committee of the Renji Hospital, Shanghai Jiao Tong University, China (Approval No. RA2021330).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"160"}}